Prospective, non‐randomised, long term clinical evaluation of a foldable hydrophilic single piece intraocular lens: results of the Centerflex FDA study
Identifieur interne : 000942 ( Pmc/Curation ); précédent : 000941; suivant : 000943Prospective, non‐randomised, long term clinical evaluation of a foldable hydrophilic single piece intraocular lens: results of the Centerflex FDA study
Auteurs : K A Becker ; M. Martin ; T M Rabsilber ; B B Entz ; A J Reuland ; G U AuffarthSource :
- The British Journal of Ophthalmology [ 0007-1161 ] ; 2006.
Abstract
Owing to the improvement of modern intraocular lenses (IOLs) in terms of design and material, posterior capsule opacification (PCO) usually takes 2–3 years to develop. Thus, long term clinical evaluation of new implants is important.
As part of a prospective, non‐randomised FDA trial, the Rayner Centerflex, a foldable hydrophilic acrylic, single piece IOL was implanted in one eye of 83 patients (mean age 73.5 (SD 7.0) years). Over 3 years postoperatively, a standardised FDA protocol concerning IOL safety and efficacy was followed including evaluation of spherical equivalent (SE), best corrected distance visual acuity (BCDVA), endothelial cell count (ECC), flare meter values, PCO development, and anterior capsule shrinkage.
Postoperatively, mean SE was stable ranging between −0.3D and 0.17D. After 1–2 months, all patients achieved a BCDVA of 20/40 or better. At 3–6 months postoperatively, mean ECC decreased from 2612 (SD 346) cells/mm2 to 2380 (316) cells/mm2. Mean PCO score for the entire optic increased from 0.20 (0.20) months (3–6 months postoperatively) to 0.87 (0.57) resulting in a Nd:YAG rate of 29.41% after 3 years. No anterior capsule shrinkage was found.
The Centerflex showed excellent functional results, low values for endothelial cell loss and inflammatory signs, and no anterior capsule shrinkage. PCO formation was higher compared to other IOLs, which could be explained by the incomplete sharp edge at the optic‐haptic junctions representing an “Achilles' heel” for cell ingrowth.
Url:
DOI: 10.1136/bjo.2006.092437
PubMed: 16687454
PubMed Central: 1857197
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000942
Links to Exploration step
PMC:1857197Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Prospective, non‐randomised, long term clinical evaluation of a foldable hydrophilic single piece intraocular lens: results of the Centerflex FDA study</title><author><name sortKey="Becker, K A" sort="Becker, K A" uniqKey="Becker K" first="K A" last="Becker">K A Becker</name></author><author><name sortKey="Martin, M" sort="Martin, M" uniqKey="Martin M" first="M" last="Martin">M. Martin</name></author><author><name sortKey="Rabsilber, T M" sort="Rabsilber, T M" uniqKey="Rabsilber T" first="T M" last="Rabsilber">T M Rabsilber</name></author><author><name sortKey="Entz, B B" sort="Entz, B B" uniqKey="Entz B" first="B B" last="Entz">B B Entz</name></author><author><name sortKey="Reuland, A J" sort="Reuland, A J" uniqKey="Reuland A" first="A J" last="Reuland">A J Reuland</name></author><author><name sortKey="Auffarth, G U" sort="Auffarth, G U" uniqKey="Auffarth G" first="G U" last="Auffarth">G U Auffarth</name></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">16687454</idno><idno type="pmc">1857197</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1857197</idno><idno type="RBID">PMC:1857197</idno><idno type="doi">10.1136/bjo.2006.092437</idno><date when="2006">2006</date><idno type="wicri:Area/Pmc/Corpus">000942</idno><idno type="wicri:Area/Pmc/Curation">000942</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Prospective, non‐randomised, long term clinical evaluation of a foldable hydrophilic single piece intraocular lens: results of the Centerflex FDA study</title><author><name sortKey="Becker, K A" sort="Becker, K A" uniqKey="Becker K" first="K A" last="Becker">K A Becker</name></author><author><name sortKey="Martin, M" sort="Martin, M" uniqKey="Martin M" first="M" last="Martin">M. Martin</name></author><author><name sortKey="Rabsilber, T M" sort="Rabsilber, T M" uniqKey="Rabsilber T" first="T M" last="Rabsilber">T M Rabsilber</name></author><author><name sortKey="Entz, B B" sort="Entz, B B" uniqKey="Entz B" first="B B" last="Entz">B B Entz</name></author><author><name sortKey="Reuland, A J" sort="Reuland, A J" uniqKey="Reuland A" first="A J" last="Reuland">A J Reuland</name></author><author><name sortKey="Auffarth, G U" sort="Auffarth, G U" uniqKey="Auffarth G" first="G U" last="Auffarth">G U Auffarth</name></author></analytic><series><title level="j">The British Journal of Ophthalmology</title><idno type="ISSN">0007-1161</idno><idno type="eISSN">1468-2079</idno><imprint><date when="2006">2006</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><sec><title>Background</title><p>Owing to the improvement of modern intraocular lenses (IOLs) in terms of design and material, posterior capsule opacification (PCO) usually takes 2–3 years to develop. Thus, long term clinical evaluation of new implants is important.</p></sec><sec><title>Methods</title><p>As part of a prospective, non‐randomised FDA trial, the Rayner Centerflex, a foldable hydrophilic acrylic, single piece IOL was implanted in one eye of 83 patients (mean age 73.5 (SD 7.0) years). Over 3 years postoperatively, a standardised FDA protocol concerning IOL safety and efficacy was followed including evaluation of spherical equivalent (SE), best corrected distance visual acuity (BCDVA), endothelial cell count (ECC), flare meter values, PCO development, and anterior capsule shrinkage.</p></sec><sec><title>Results</title><p>Postoperatively, mean SE was stable ranging between −0.3D and 0.17D. After 1–2 months, all patients achieved a BCDVA of 20/40 or better. At 3–6 months postoperatively, mean ECC decreased from 2612 (SD 346) cells/mm<sup>2</sup> to 2380 (316) cells/mm<sup>2</sup>. Mean PCO score for the entire optic increased from 0.20 (0.20) months (3–6 months postoperatively) to 0.87 (0.57) resulting in a Nd:YAG rate of 29.41% after 3 years. No anterior capsule shrinkage was found.</p></sec><sec><title>Conclusion</title><p>The Centerflex showed excellent functional results, low values for endothelial cell loss and inflammatory signs, and no anterior capsule shrinkage. PCO formation was higher compared to other IOLs, which could be explained by the incomplete sharp edge at the optic‐haptic junctions representing an “Achilles' heel” for cell ingrowth.</p></sec></div></front></TEI><pmc article-type="case-report"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Ophthalmol</journal-id><journal-title>The British Journal of Ophthalmology</journal-title><issn pub-type="ppub">0007-1161</issn><issn pub-type="epub">1468-2079</issn><publisher><publisher-name>BMJ Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">16687454</article-id><article-id pub-id-type="pmc">1857197</article-id><article-id pub-id-type="publisher-id">bj92437</article-id><article-id pub-id-type="doi">10.1136/bjo.2006.092437</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Science - Scientific Report</subject></subj-group></article-categories><title-group><article-title>Prospective, non‐randomised, long term clinical evaluation of a foldable hydrophilic single piece intraocular lens: results of the Centerflex FDA study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Becker</surname><given-names>K A</given-names></name></contrib><contrib contrib-type="author"><name><surname>Martin</surname><given-names>M</given-names></name></contrib><contrib contrib-type="author"><name><surname>Rabsilber</surname><given-names>T M</given-names></name></contrib><contrib contrib-type="author"><name><surname>Entz</surname><given-names>B B</given-names></name></contrib><contrib contrib-type="author"><name><surname>Reuland</surname><given-names>A J</given-names></name></contrib><contrib contrib-type="author"><name><surname>Auffarth</surname><given-names>G U</given-names></name></contrib></contrib-group><aff><bold>K A Becker</bold>,<bold>M Martin</bold>,<bold>T M Rabsilber</bold>,<bold>B B Entz</bold>,<bold>A J Reuland</bold>,<bold>G U Auffarth</bold>, Heidelberg IOL and Refractive Surgery Research Group, Department of Ophthalmology, Ruprecht‐Karls‐University of Heidelberg, Germany</aff><author-notes><corresp>Correspondence to: Gerd U Auffarth<break></break>MD, Department of Ophthalmology, Ruprecht‐Karls‐University of Heidelberg, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany; gerd.auffarth@med.uni‐heidelberg.de</corresp></author-notes><pub-date pub-type="ppub"><month>8</month><year>2006</year></pub-date><volume>90</volume><issue>8</issue><fpage>971</fpage><lpage>974</lpage><history><date date-type="accepted"><day>4</day><month>4</month><year>2006</year></date></history><permissions><copyright-statement>Copyright © 2006 BMJ Publishing Group</copyright-statement></permissions><abstract><sec><title>Background</title><p>Owing to the improvement of modern intraocular lenses (IOLs) in terms of design and material, posterior capsule opacification (PCO) usually takes 2–3 years to develop. Thus, long term clinical evaluation of new implants is important.</p></sec><sec><title>Methods</title><p>As part of a prospective, non‐randomised FDA trial, the Rayner Centerflex, a foldable hydrophilic acrylic, single piece IOL was implanted in one eye of 83 patients (mean age 73.5 (SD 7.0) years). Over 3 years postoperatively, a standardised FDA protocol concerning IOL safety and efficacy was followed including evaluation of spherical equivalent (SE), best corrected distance visual acuity (BCDVA), endothelial cell count (ECC), flare meter values, PCO development, and anterior capsule shrinkage.</p></sec><sec><title>Results</title><p>Postoperatively, mean SE was stable ranging between −0.3D and 0.17D. After 1–2 months, all patients achieved a BCDVA of 20/40 or better. At 3–6 months postoperatively, mean ECC decreased from 2612 (SD 346) cells/mm<sup>2</sup> to 2380 (316) cells/mm<sup>2</sup>. Mean PCO score for the entire optic increased from 0.20 (0.20) months (3–6 months postoperatively) to 0.87 (0.57) resulting in a Nd:YAG rate of 29.41% after 3 years. No anterior capsule shrinkage was found.</p></sec><sec><title>Conclusion</title><p>The Centerflex showed excellent functional results, low values for endothelial cell loss and inflammatory signs, and no anterior capsule shrinkage. PCO formation was higher compared to other IOLs, which could be explained by the incomplete sharp edge at the optic‐haptic junctions representing an “Achilles' heel” for cell ingrowth.</p></sec></abstract><kwd-group><kwd>posterior capsule opacification</kwd><kwd>intraocular lens</kwd><kwd>hydrophilic acrylic</kwd><kwd>single piece intraocular lens</kwd></kwd-group></article-meta></front></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Ticri/CIDE/explor/HapticV1/Data/Pmc/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000942 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Curation/biblio.hfd -nk 000942 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Ticri/CIDE
|area= HapticV1
|flux= Pmc
|étape= Curation
|type= RBID
|clé= PMC:1857197
|texte= Prospective, non‐randomised, long term clinical evaluation of a foldable hydrophilic single piece intraocular lens: results of the Centerflex FDA study
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Curation/RBID.i -Sk "pubmed:16687454" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Curation/biblio.hfd \
| NlmPubMed2Wicri -a HapticV1
| This area was generated with Dilib version V0.6.23. |  |